Most UCs, such as prostate, bladder, and renal cell carcinomas, are P53-deficient, and DNA-PK inhibitors protect normal cells with P53-dependent proliferation from mitotic death (Leszczynska et al., 2015; Jung et al., 2021; He et al., 2022b; Chaudagar et al., 2023). Here, TP53 is linked to renal cell carcinoma.